Pharmacophore-based design and discovery of (−)-meptazinol carbamates as dual modulators of cholinesterase and amyloidogenesis

References

• Bartus RT, Dean RL, 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408–14.
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184–5.
   PubMed Web of Science ®Google Scholar
• Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986;83:4913–17.
   PubMed Web of Science ®Google Scholar
• Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011;1:a006189.
   PubMed Web of Science ®Google Scholar
• Kiren U, Eliezer M. Alzheimer’s disease: recent advances and future perspectives. J Alzheimers Dis 2013;33:S185–94.
   PubMed Web of Science ®Google Scholar
• Karran E. Current status of vaccination therapies in Alzheimer's disease. J Neurochem 2012;123:647–51.
   PubMed Web of Science ®Google Scholar
• Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010;9:702–16.
   PubMed Web of Science ®Google Scholar
• Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008;51:347–72.
   PubMed Web of Science ®Google Scholar
• Bajda M, Guzior N, Ignasik M, Malawska B. Multi-target-directed ligands in Alzheimer's disease treatment. Curr Med Chem 2001;18:4949–75.
   Web of Science ®Google Scholar
• León R, Garcia AG, Marco-Contelles J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. Med Res Rev 2013;33:139–89.
   PubMed Web of Science ®Google Scholar
• Rampa A, Belluti F, Gobbi S, Bisi A. Hybrid-based multi-target ligands for the treatment of Alzheimer's disease. Curr Top Med Chem 2011;11:2716–30.
   PubMed Web of Science ®Google Scholar
• Klein J. Phenserine. Expert Opin Investig Drugs 2007;16:1087–97.
   PubMed Web of Science ®Google Scholar
• Greig NH, Sambamurti K, Yu QS, et al. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2005;2:281–90.
   PubMedGoogle Scholar
• Shaw KT, Utsuki T, Rogers J, et al. Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 2001;98:7605–10.
   PubMed Web of Science ®Google Scholar
• Winblad B, Giacobini E, Frolich L, et al. Phenserine efficacy in Alzheimer's disease. J Alzheimers Dis 2010;22:1201–8.
   PubMed Web of Science ®Google Scholar
• Becker RE, Greig NH. Was phenserine a failure or were investigators mislead by methods? Curr Alzheimer Res 2012;9:1174–81.
   PubMed Web of Science ®Google Scholar
• Xie Q, Wang H, Xia Z, et al. Bis-(−)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem 2008;51:2027–36.
   PubMed Web of Science ®Google Scholar
• Paz A, Xie Q, Greenblatt HM, et al. The crystal structure of a complex of acetylcholinesterase with a bis-(−)-nor-meptazinol derivative reveals disruption of the catalytic triad. J Med Chem 2009;52:2543–9.
   PubMed Web of Science ®Google Scholar
• Liu T, Xia Z, Zhang WW, et al. Bis(9)-(−)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice. Pharmacol Biochem Behav 2013;104:138–43.
   PubMed Web of Science ®Google Scholar
• Zheng W, Li J, Qiu Z, et al. Novel bis-(−)-nor-meptazinol derivatives act as dual binding site AChE inhibitors with metal-complexing property. Toxicol Appl Pharmacol 2012;264:65–72.
   PubMed Web of Science ®Google Scholar
• Yu QS, Greig NH, Holloway HW, et al. (−)-(3aS)-Eseroline carbamate (II), a potent cholinesterase inhibitor and close analogue of physostigmine: reanalysis. Med Chem Res 2000;10:186–99.
   Web of Science ®Google Scholar
• Yu Q, Greig NH, Holloway HW. Syntheses and anticholinesterase activities of (3aS)-N1, N8-bisnorphenserine, (3aS)-N1,N8-bisnorphysostigmine, their antipodal isomers, and other potential metabolites of phenserine. J Med Chem 1998;41:2371–9.
   PubMed Web of Science ®Google Scholar
• Yu Q, Holloway HW, Flippen-Anderson JL, et al. Methyl analogues of the experimental Alzheimer drug Phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. J Med Chem 2001;44:4062–71.
   PubMed Web of Science ®Google Scholar
• Pei XF, Greig NH, Brossi A. Synthesis and biological evaluation of (±)-3a-phenyl congeners of physostigmine and phenserine. Heterocycles 1998;49:437–44.
   Web of Science ®Google Scholar
• Luo W, Yu Q, Kulkarni SS, et al. Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (−)- and (+)-tetrahydro furobenzofuran and methanobenzodioxepine. J Med Chem 2006;49:2174–85.
   PubMed Web of Science ®Google Scholar
• Chen YL, Nielsen J, Hedberg K, et al. Syntheses, resolution, and structure-activity relationships of potent acetylcholinesterase inhibitors: 8-carbaphysostigmine analogues. J Med Chem 1992;35:1429–34.
   PubMed Web of Science ®Google Scholar
• Weinstock M, Razin M, Chorev M, Tashma Z, Pharmacological activity of novel acetylcholinesterase agents of potential use in the treatment of Alzheimer's Disease. In: Fisher A, Hanin I, Lachman P, eds. Advances in behavioral biology. Plenum Press: New York; 1986:539–551.
   Google Scholar
• (a) Bolognesi ML, Bartolini M, Cavalli A, et al. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. J Med Chem 2004;47:5945–52; (b)
   PubMed Web of Science ®Google Scholar
  Bolognesi ML, Andrisano V, Bartolini M, et al. Heterocyclic inhibitors of AChE acylation and peripheral sites. Il Farmaco 2005;60:465–73.
   PubMedGoogle Scholar
• Sterling J, Herzig Y, Goren T, et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem 2002;45:5260–79.
   PubMed Web of Science ®Google Scholar
• Yu Q, Pei XF, Holloway HW, Greig NH. Total syntheses and anticholinesterase activities of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues. J Med Chem 1997;40:2895–901.
   PubMed Web of Science ®Google Scholar
• Yu Q, Luo W, Holloway HW, et al. Racemic N1-norphenserine and its enantiomers: unpredicted inhibition of human acetyl- and butyrylcholinesterase and β-amyloid precursor protein in vitro. Heterocycles 2003;61:529–39.
   Web of Science ®Google Scholar
• Mustazza C, Borioni A, Giudice MRD, et al. Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease. Eur J Med Chem 2002;37:91–109.
   PubMed Web of Science ®Google Scholar
• Roy KK, Tota S, Nath C, et al. Substituted 1,2,3,4-tetrahydroquinolin-7-yl carbamates as acetylcholinesterase inhibitors for treatment of alzheimer's disease. US20130324573 A1, 2012.
   Google Scholar
• Lerman L, Nudelman A, Shalom H, et al. Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's Disease. J Med Chem 2012;55:10700–15.
   PubMed Web of Science ®Google Scholar
• Borioni A, Giudice MRD, Mustazza C, Gatta F. Synthesis of bicyclic azacompounds (3-dimethylcarbamoyloxyphenyl) substituted as acetylcholinesterase inhibitors. J Heterocyclic Chem 2000;37:799–810.
   Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V, Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• Gorun V, Proinov I, Baltescu V, et al. Modified Ellman procedure for assay of cholinesterases in crude enzymatic preparations. Anal Biochem 1978;86:324–6.
   PubMed Web of Science ®Google Scholar
• (a) Göçer H, Akincioğlu A, Göksu S, et al. Carbonic anhydrase and acetylcholinesterase inhibitory effects of carbamates and sulfamoylcarbamates. J Enzyme Inhib Med Chem 2015;30:316–20; (b)
   PubMed Web of Science ®Google Scholar
  Özgeriş B, Göksu S, Polat Köse L, et al. Acetylcholinesterase and carbonic anhydrase inhibitory properties of novel urea and sulfamide derivatives incorporating dopaminergic 2-aminotetralin scaffolds. Bioorg Med Chem 2016;24:2318–29; (c)
   PubMed Web of Science ®Google Scholar
  Akıncıoğlu A, Akıncıoğlu H, Gülçin İ, et al. Discovery of potent carbonic anhydrase and acetylcholine esterase inhibitors: novel sulfamoylcarbamates and sulfamides derived from acetophenones. Bioorg Med Chem 2015;23:3592–602.
   PubMed Web of Science ®Google Scholar
• Bartolini M, Cavrini V, Andrisano V. Choosing the right chromatographic support in making a new acetylcholinesterase-micro-immobilised enzyme reactor for drug discovery. J Chromatogr A 2005;1065:135–44.
   PubMed Web of Science ®Google Scholar
• Bartolini M, Cavrini V, Andrisano V. Characterization of reversible and pseudo-irreversible acetylcholinesterase inhibitors by means of an immobilized enzyme reactor. J Chromatogr A 2007;1144:102–10.
   PubMed Web of Science ®Google Scholar
• Feaster SR, Quinn DM. Mechanism-based inhibitors of mammalian cholesterol esterase. Method Enzymol 1997;286:231–52.
   PubMed Web of Science ®Google Scholar
• Ashani Y, Peggins JO, 3rd, Doctor BP. Mechanism of inhibition of cholinesterases by huperzine A. Biochem Biophys Res Commun 1992;184:719–26.
   PubMed Web of Science ®Google Scholar
• Perola E, Cellai L, Lamba D, et al. Long chain analogs of physostigmine as potential drugs for Alzheimer's disease: new insights into the mechanism of action in the inhibition of acetylcholinesterase. Biochim Biophys Acta 1997;1343:41–50.
   PubMed Web of Science ®Google Scholar
• Jia H, Jiang Y, Ruan Y, et al. Tenuigenin treatment decreases secretion of the Alzheimer's disease amyloid beta-protein in cultured cells. Neurosci Lett 2004;367:123–8.
   PubMed Web of Science ®Google Scholar
• Bartolucci C, Stojan J, Yu QS, et al. Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group. Biochem J 2012;444:269–77.
   PubMed Web of Science ®Google Scholar
• Li W, Xu L-L, Xie Q, et al. Theoretical and NMR investigations on the conformations of (−)-meptazinol hydrochloride in solution. Mol Simul 2013;39:1065–9.
   Web of Science ®Google Scholar
• Bartolini M, Cavrini V, Andrisano V. Monolithic micro-immobilized-enzyme reactor with human recombinant acetylcholinesterase for on-line inhibition studies. J Chromatogr A 2004;1031:27–34.
   PubMed Web of Science ®Google Scholar
• Herkert NM, Thiermann H, Worek F. In vitro kinetic interactions of pyridostigmine, physostigmine and soman with erythrocyte and muscle acetylcholinesterase from different species. Toxicol Lett 2011;206:41–6.
   PubMed Web of Science ®Google Scholar
• Ariel N, Ordentlich A, Barak D, et al. The ‘aromatic patch’ of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors. Biochem J 1998;335:95–102.
   PubMed Web of Science ®Google Scholar
• Barak D, Ordentlich A, Stein D, et al. Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions. Biochem J 2009;417:213–22.
   PubMed Web of Science ®Google Scholar
• Lahiri DK, Chen D, Maloney B, et al. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther 2007;320:386–96.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Gardoni F, Marcello E, et al. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem 2004;90:1489–99.
   PubMed Web of Science ®Google Scholar
• Schmitz A, Tikkanen R, Kirfel G, Herzog V. The biological role of the Alzheimer amyloid precursor protein in epithelial cells. Histochem Cell Biol 2002;117:171–80.
   PubMed Web of Science ®Google Scholar
• Lynch WT, Coon JM. Effect of tri-0-tolyl phosphate pretreatment on the toxicity and metabolism of parathion and paraoxon in mice. Toxicol Appl Pharmacol 1972;21:153–65.
   PubMed Web of Science ®Google Scholar
• Holloway HW, Ingram DK, Maccecchini ML, Greig NH. Posiphen® and analogs: experimental Alzheimer agents that reduce amyloid-β peptide by lowering amyloid precursor protein levels in culture and in vivo. 42nd Annual Winter Conference on Brain Research (WCBR); 2009 Jan 24–30; Copper Mountain, CO.
   Google Scholar